Clincosm LogoSign in Get a demo

EGFR Positive Non-small Cell Lung Cancer

Showing 1 - 15 of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

Recruiting
  • Non-small Cell Lung Cancer Stage III
  • +2 more
  • Busan, Korea, Republic of
  • +9 more
Jun 30, 2022

NSCLC, EGFR Positive NSCLC, Oligoprogression Trial in München (Osimertinib, Radiotherapy)

Recruiting
  • NSCLC
  • +2 more
  • München, Germany
    LMU Klinikum der Universität München
May 17, 2022

Stage IV NSCLC, Targeted Therapy, Nonsmall Cell Lung Cancer Trial in Boston (POISE)

Not yet recruiting
  • Stage IV Non-small Cell Lung Cancer
  • +7 more
  • POISE
  • Boston, Massachusetts
    Massachusetts General Hospital
Apr 13, 2022

EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)

Active, not recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Advanced Solid Tumors, EGFR Positive NSCLC, Colorectal Carcinoma Trial in United States (TP-0903)

Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
Apr 4, 2022

EGFR Positive NSCLC Trial in China (APG-1252, Osimertinib Mesylate Tablets)

Recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
  • +3 more
Oct 27, 2021

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

Recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Hong Kong, Hong Kong
  • +8 more
Sep 20, 2021

Osimertinib for Advanced EGFR-positive NSCLC Patients

Recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Non Small Cell Lung Cancer
    • Singapore, Singapore
      National University Hospital
    Aug 31, 2021

    EGFR Positive NSCLC Trial in Korea, Republic of (EGFR)

    Active, not recruiting
    • EGFR Positive Non-small Cell Lung Cancer
    • Anyang, Gyeonggi-do, Korea, Republic of
    • +7 more
    Jul 13, 2021

    EGFR Positive NSCLC, Brain Metastases Trial in Hangzhou (Almonertinib)

    Not yet recruiting
    • EGFR Positive Non-small Cell Lung Cancer
    • Brain Metastases
    • Hangzhou, Zhejiang, China
      Hangzhou Cancer Hospital
    Nov 19, 2020

    Workup at Disease Progression and Implementation of Osimertinib

    Unknown status
    • EGFR Positive Non-small Cell Lung Cancer
      • Heidelberg, Germany
        Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg
      Mar 9, 2020

      EGFR Positive NSCLC, Adenocarcinoma Trial in Beijing (Icotinib, Placebo)

      Unknown status
      • EGFR Positive Non-small Cell Lung Cancer
      • Adenocarcinoma
      • Beijing, Beijing, China
      • +10 more
      Jul 12, 2018

      Lung Adenocarcinoma, EGFR Positive NSCLC Trial (EGFR-TKI, Thoracic Hypofractionated Radiotherapy)

      Unknown status
      • Lung Adenocarcinoma
      • EGFR Positive Non-small Cell Lung Cancer
      • EGFR-TKI
      • Thoracic Hypofractionated Radiotherapy
      • (no location specified)
      May 26, 2016

      EGFR Positive NSCLC, Adenocarcinoma Trial in China (Sequential Icotinib Plus Chemotherapy, Icotinib)

      Unknown status
      • EGFR Positive Non-small Cell Lung Cancer
      • Adenocarcinoma
      • Sequential Icotinib Plus Chemotherapy
      • Icotinib
      • Lanzhou, Gansu, China
      • +30 more
      Apr 27, 2015

      EGFR Positive NSCLC, Adenocarcinoma Trial in NanNing (Sequential and maintenance icotinib, Maintenance icotinib)

      Unknown status
      • EGFR Positive Non-small Cell Lung Cancer
      • Adenocarcinoma
      • Sequential and maintenance icotinib
      • Maintenance icotinib
      • NanNing, Guangxi, China
        First Affiliated Hospital of Guangxi Medical University
      Jul 17, 2014